Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06506942 · ClinicalTrials.gov registry record · NA

The TRICURE EFS Study

A NA study of Cardiovascular Diseases and Heart Valve Diseases, sponsored by TRiCares.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
8
Study locations

NCT06506942 is a NA study of Cardiovascular Diseases and Heart Valve Diseases that is actively recruiting participants, run by TRiCares. The registered enrollment target is 15 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06506942, a NA study of Cardiovascular Diseases and Heart Valve Diseases, is actively recruiting participants, sponsored by TRiCares.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
8
Study locations

Study Summary

Prospective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System

Interventions

  • DEVICE Transcatheter Tricuspid Valve Replacement

Study Locations (8)

New York

  • Columbia University Medical Center/ NewYork Presbyterian Hospital - New York
  • Montefiore - The Bronx

Georgia

  • Piedmont Healthcare Inc. - Atlanta

Illinois

  • Northwestern - Chicago

Michigan

  • University of Michigan Hospital and Health Systems - Ann Arbor

Minnesota

  • Minneapolis Heart Institute Foundation - Minneapolis

Ohio

  • The Christ Hospital - Cincinnati

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-09-11
Est. Completion 2031-03
Phase NA

Sponsor

TRiCares

1 total trials

What the Registry Record Tells You About NCT06506942

The ClinicalTrials.gov registry entry for NCT06506942 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is TRiCares, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Transcatheter Tricuspid Valve Replacement is the first listed.

NCT06506942 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT06506942 about?

NCT06506942 is a clinical study titled "The TRICURE EFS Study". Prospective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System

What is the current status of trial NCT06506942?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-09-11. Estimated completion is 2031-03.

What conditions does trial NCT06506942 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Valve Diseases, Tricuspid Valve Regurgitation.

What interventions are being tested in trial NCT06506942?

The interventions under investigation include: Transcatheter Tricuspid Valve Replacement (DEVICE).

Who is sponsoring clinical trial NCT06506942?

This trial is sponsored by TRiCares, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06506942 being conducted?

This trial has 8 study locations across Georgia, Illinois, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.